VARIVAX
Biological
Merck Sharp & Dohme Corporation
Total Payments
$2.9M
Transactions
2,446
Doctors
469
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $13,798 | 112 | 23 |
| 2023 | $5,389 | 294 | 273 |
| 2022 | $4,420 | 37 | 0 |
| 2021 | $617.68 | 39 | 0 |
| 2020 | $5,019 | 23 | 18 |
| 2019 | $260,651 | 256 | 60 |
| 2018 | $2.4M | 1,151 | 52 |
| 2017 | $192,944 | 534 | 53 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.9M | 1,845 | 99.1% |
| Food and Beverage | $12,181 | 553 | 0.4% |
| Travel and Lodging | $11,585 | 47 | 0.4% |
| Consulting Fee | $1,000 | 1 | 0.0% |
Payments by Type
Research
$2.9M
1,845 transactions
General
$24,766
601 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II | Merck Sharp & Dohme Corporation | $2.9M | 0 |
| A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of Varivax New Seed Process NSP Administered Concomitantly with M-M-R II | Merck Sharp & Dohme Corporation | $14,960 | 0 |
| A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II | Merck Sharp & Dohme LLC | $4,420 | 0 |
Top Doctors Receiving Payments for VARIVAX — Page 19
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Family Medicine | Mission Hills, CA | $10.82 | 1 |
| , DO | Obstetrics & Gynecology | Mission Hills, CA | $10.82 | 1 |
| , MD | Obstetrics & Gynecology | Mission Hills, CA | $10.82 | 1 |
| , MD | Neurology | Mission Hills, CA | $10.82 | 1 |
| , MD | Family Medicine | East Providence, RI | $10.65 | 1 |
| , M.D | Pediatrics | St Louis, MO | $10.57 | 1 |
| , MD | Family Medicine | Phoenix, AZ | $10.56 | 1 |
| , MD | Internal Medicine | Scottsdale, AZ | $10.56 | 1 |
| , MD | Pediatrics | Mentor, OH | $10.48 | 1 |
| , MD | Pediatrics | Mentor, OH | $10.48 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Mentor, OH | $10.48 | 1 |
| , M.D | Pediatrics | Mentor, OH | $10.48 | 1 |
| , MD | Pediatrics | Mentor, OH | $10.48 | 1 |
| , M.D., MPH | Student in an Organized Health Care Education/Training Program | Cleveland, OH | $10.33 | 1 |
| , M.D | Family Medicine | Los Alamitos, CA | $9.79 | 1 |
| , M.D | Family Medicine | Los Alamitos, CA | $9.79 | 1 |
| , M.D | Family Medicine | Youngstown, OH | $8.37 | 1 |
| Paul Rich | — | Youngstown, OH | $8.37 | 1 |
| , M.D | Family Medicine | Youngstown, OH | $8.37 | 1 |
| , MD | Internal Medicine | Garner, NC | $8.07 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $2.9M
- Merck Sharp & Dohme LLC $23,607
Product Information
- Type Biological
- Total Payments $2.9M
- Total Doctors 469
- Transactions 2,446
About VARIVAX
VARIVAX is a biological associated with $2.9M in payments to 469 healthcare providers, recorded across 2,446 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2024. In 2024, $13,798 was paid across 112 transactions to 23 doctors.
The most common payment nature for VARIVAX is "Unspecified" ($2.9M, 99.1% of total).
VARIVAX is associated with 3 research studies, including "A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II" ($2.9M).